Latest Depression News

Emyria’s new treatment-resistant depression program shows statistically significant symptom improvements in a small initial cohort, expanding its mental health therapy offerings beyond PTSD.

Actinogen Medical’s pivotal XanaMIA Alzheimer’s trial has passed a third independent safety review, endorsing continuation without changes. Final topline efficacy data is expected in November 2026.

Emyria Limited is progressing its national network of psychedelic-assisted therapy clinics, reporting durable patient outcomes, expanding funding sources, and benefiting from regulatory changes that broaden therapist eligibility.

Actinogen Medical has obtained positive scientific advice from the European Medicines Agency that aligns with prior FDA guidance, clarifying regulatory requirements for its Alzheimer’s drug Xanamem and paving the way for a streamlined approval process in major markets.

Nexalis Therapeutics has locked in a $53 million non-dilutive funding facility with Point8 Capital, replacing its previous lender and supporting three clinical programs targeting breakthrough cancer pain, panic disorder, and treatment-resistant depression.

Phoslock Environmental Technologies reported a sales recovery in 2025 with further growth expected, backed by resumed production in China and promising European projects, while ongoing litigation clouds the outlook.

Little Green Pharma (ASX:LGP) posted a 15.3% revenue increase to AUD 42.5 million in FY2026, driven by European market expansion, yet recorded a $1.4 million loss after tax impacted by significant inventory write-downs.

Emyria has launched its first Empax clinic in Victoria on schedule, establishing a new clinical hub with trained staff and dual reimbursement pathways to support growth.

Botanix Pharmaceuticals reported a 5% rise in Sofdra prescriptions in Q3 FY26 despite a dip in net revenue due to insurance deductible resets, strengthened by a $45 million capital raise and a new API supply deal with Piramal.

Acrux pivots from generics to developing a Female Testosterone therapy for HSDD, leveraging FDA feedback and a strong US market opportunity.

Entropy Neurodynamics has reported encouraging early clinical outcomes from its pioneering intravenous psilocin therapy for Binge Eating Disorder, alongside a patent grant that strengthens its intellectual property moat.

Ardiden Limited has secured the historic Golden Patricia Gold Mine from Barrick, consolidating a high-grade gold corridor in Ontario’s Pickle Lake district and opening significant exploration opportunities.